Leukocyte function is regulated by the final balance between activating and inhibitory signals produced continuously by immunoreceptors mostly present on the cell surface. These receptors, which usually belong to multigenic families, include molecules with extracellular Ctype lectin-like or immunoglobulin-like folds. (1) (2) (3) . Inhibitory immunoreceptors display long cytoplasmic tails containing immunoreceptor tyrosine-based inhibitory motifs (ITIM). After receptor engagement by their ligands, tyrosine residues within ITIM motifs are phosphorylated becoming docking sites for the recruitment of SH2-containing tyrosine phosphatases, such as SHP-1 and SHIP. Upon recruitment by inhibitory receptors, phosphatases become active and dephosphorylate key intracellular substrates involved in the initiation and amplification of activating responses (2) . In contrast, activating receptors usually present short cytoplasmic tails lacking any signaling motifs. Alternatively, they present a positively charged amino acid residue within their transmembrane domain that enables the interaction with immunoreceptor tyrosine-based activating motif (ITAM)-bearing adaptor proteins (FcεRγ, CD3ζ and DAP12), which contain a complementary negative charge in the same domain. Ligand-induced phosphorylation of ITAMs leads to the recruitment of tandem SH2-containing tyrosine kinases, such as Syk and ZAP-70, to transduce activating signals (1) .
The human CD300 family of immunoreceptors belongs to the superfamily of immunoglobulin receptors and the genes that encode for the different members are clustered on human chromosome 17q25.1 (4, 5) . All of them are found exclusively in myeloid cells, with the exception of CD300a that is additionally expressed in certain subsets of T and NK cells. CD300 receptors present an extracellular V-type immunoglobulin-like domain with an additional pair of cystein residues, a transmembrane region and a cytoplasmic tail. Up to now, five members of the family have been identified and fully characterized (6) (7) (8) (9) . Although initially it seemed that these molecules fitted the classical activating/inhibitory immunoreceptor model, now it is clear that this family presents a more complex behavior than expected. CD300a and CD300f receptors can be classified structurally as inhibitory receptors due to the presence of ITIMs in their cytoplasmic tails. Indeed, both molecules are able to bind SHP-1 phosphatase and consequently block activating signals promoted by activating receptors (6, 8) . Surprisingly, CD300f has the capability to recruit Grb2 and the PI3kinase p85α subunit (10) . Accordingly, a dual activating/inhibitory function has been proposed for this receptor. The mechanism(s) regulating CD300f duality is not fully understand yet. CD300b and CD300e receptors interact with the ITAM-bearing adaptor DAP12 through charge complementation between transmembrane regions and, deliver activating signals after receptor engagement with specific antibodies (8, 9, 11) . However, CD300b receptor is a nonclassical activating receptor because in addition to DAP12, it recruits the scaffold protein Grb2 through a tyrosine-based motif present in the cytoplasmic tail. The recruitment of both signaling molecules are independent events and define two different signaling pathways (9) . Finally, CD300c, the first cloned member of the CD300 family, displays a short cytoplasmic tail in combination with a transmembrane region bearing a negatively charged residue which theoretically would avoid transmembrane charge complementation with the known adaptor polypeptides (7) . Nevertheless, we have shown recently that CD300c is able to recruit FcεRγ polypeptide through a different mechanism and consequently acts as an activating receptor (12) . In addition, we have demonstrated that this family of receptors interact extracellularly forming homo-and hetero-signaling complexes (12) . This feature has not been reported in other immunoreceptors cluster and constitutes a novel mechanism to regulate the leukocyte function. In this study we report the cloning and molecular characterization of CD300d, the sixth member of the human CD300 family. Regarding its function, our data suggests that CD300d would regulate the expression of other CD300 molecules and the composition of CD300 complexes on the cell surface.
HRP-linked anti-FLAG M2® mAb from Sigma. HRP-conjugated anti-mouse goat polyclonal and anti-rabbit donkey polyclonal were obtained from GE Healthcare. FITCconjugated anti-mouse rabbit polyclonal was from DAKO. Streptavidin-HRP was purchased from Roche. Anti-human GRP-78 (H129) rabbit polyclonal was from Santa Cruz Biotechnology. Alexa Fluor 594-conjugated anti-rabbit was from Molecular Probes. Anti-HA (12CA5) mAb and anti-Myc (9E10) mAb were described before (12) . Cloning of human CD300d and DNA constructs -Constructions used in this study were generated by PCR according to the following conditions: 94ºC for 3 min, and 30 cycles of 94ºC for 30 sec, 58ºC for 30 sec and 72ºC for 1 min using Pfu DNA Polymerase (Promega). PCR products were resolved in 1% agarose gels and visualized by ethidium bromide staining, and further confirmed by DNA sequencing under Big Dye TM cycling conditions on an Applied Biosystems 3730xl DNA Analyzer (Macrogen Inc). Details have been summarized in Supplemental Table I . Full-length CD300d (including 5' and 3' untranslated regions) was amplified from human monocytes cDNA and cloned into the pcDNA3.1-V5-His TOPO (Invitrogen), and then, the molecule without signal peptide was subcloned into pDisplay and pCDNA3-FLAG vectors. pDisplay/CD300d (R173S, E173A and F168L-F170V) and pcDNA3-FLAG/FcεRγ D29A substitution mutants were generated by PCR amplification with mutagenic oligonucleotides according to the instructions of the QuickChange SiteDirected Mutageneesis Kit (Stratagene). Chimerical molecules CD300c/d (immunoglobulin domain, stem and transmembrane region from hCD300c and the cytoplasmic tail of hCD300d) and CD300d/f (immunoglobulin domain and stem region of hCD300d and the transmembrane and cytoplasmic tail of hCD300f) were generated by PCR amplification and annealing of the overlapping ends and cloned into the pDisplay vector. Full length CD300c, CD300d and CD300f were cloned into the pEGFP-N3 vector. pDisplay/CD300a (12), -CD300b (9) -CD300c WT and ∆Cyto (del209-224aa) (12) , -CD300e (8), -CD300f (13); pCDNA3-Flag/CD300a, -CD300b, -CD300c, -CD300e, -CD300f and -FcεRγ (12), pcDNA3-Flag/DAP12 (9) , and pBabePuro-2xMyc/CD300c (12) were described before. Real time PCR -RNA from cell lines was extracted with TRIzol reagent (Invitrogen), treated with DNAseI Amplification Grade (Invitrogen) and retrotranscribed using HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's instructions. Real-time PCR for CD300d transcript detection was performed using TaqMan Gene Expression Assay (Applied Biosystems) on an ABIPrism 7500 Sequence Detector (Applied Biosystems). 18S amplification control was used for cycle normalization. Data were analyzed with 7500 SDS Software (Applied Biosystems). All PCR reactions were set up in triplicates. Mononuclear cell isolation and monocyte differentiation -Human peripheral blood mononuclear cells (PBMC) were purified from buffy coats provided by the Banc de Sang i Teixits (Barcelona, Spain). Samples were diluted 1:4 with PBS and mononuclear cells were isolated by Ficoll-paque (GE Healthcare) density gradient centrifugation. For isolation of monocytes, PBMC were resuspended at a final concentration of 10×10 6 /ml in RPMI 1640 with 10% FCS and allowed to adhere to plastic for 1h at 37ºC. Non-adherent cells were removed and attached cells were washed twice with PBS. Monocyte-enriched cell populations were then cultured for 5 days in the presence of 20 ng/ml of GM-CSF. Cells were cultured for two additional days in complete RPMI 1640 medium in the presence of the following cytokines: 25 ng/ml IFN-γ and 100 ng/ml LPS (M1ca); 20 ng/ml IL4 (M2a/IL-4); 20ng/ml IL-13 (M2a/IL-13); 20ng/ml IL-10 (M2c). Cell differentiation was monitorized by assessing specific cell surface markers. Isolation of NK, T and B cells and granulocytes from human PBMC was carried out as described (9, 14 Immunoprecipitation and western blottingCells were lysed at 4ºC for 15 min using 1% Tx-100 containing buffer described previously (15) . Cell lysates were clarified by centrifugation at 14,000×g for 15 min at 4ºC and further precleared for 1 h at 4ºC using 20µL of protein G-Sepharose beads (Amersham Biosciences) and 5µg of mouse IgG (Sigma-Aldrich,St Louis, MS, USA). Two additional pre-clearings were carried out for 30min at 4ºC with 20µL of protein GSepharose beads. For immunoprecipitations, precleared lysates were incubated with 30µL of protein G-Sepharose beads and 1µg of Ab for 3 h at 4ºC. Proteins in the crude lysates (2%) and immunoprecipitates were separated by SDS-PAGE and transferred onto PVDF filters (Millipore). Filters were blocked for 1h with 5% skim-milk or 3% bovine serum albumin (Sigma-Aldrich) and then probed with the indicated antibodies. Bound antibodies were detected using enhanced chemiluminescence reagent (Pierce). Statistical analysis -Descriptive data were expressed as the arithmetic mean plus and minus the standard error of the mean (mean ± SEM). GraphPad Prism statistical package (v5.0) was used to investigate group differences by unpaired Student's t test. p values are indicated for statistically different means.
RESULTS
Cloning and sequence analysis of human CD300d -With the aim of identifying new members of the CD300 family, we used the sequences of known human CD300 molecules to blast the Ensembl genome database 2 . The search resulted in a cDNA encoding for a novel putative CD300 receptor termed CD300d. We designed primers to amplify the putative nucleotide sequence from cDNA obtained from human monocytes. The 644bp PCR product contained an open reading frame of 585bp encoding for a protein of 194 aa with a predicted molecular mass of 21.5 kDa (EF137868) (Fig 1A) . Sequence analysis revealed CD300d as a type I transmembrane receptor driven by a signal peptide 18 aa in length (SignalP 3.0 server 3 ). The extracellular region of CD300d presents a single Ig V-type domain followed by a 41 aa membrane-proximal or stem region. The Ig domain contains two potential Nglycosylation sites, whereas the stem area displays seventeen putative O-glycosylation sites (NetNGlyc 1.0 and NetOGlyc 3.1 servers 3 ). CD300d, like all the CD300 family members, displays an additional pair of cysteines within the immunoglobulin domain (Cys 50 and Cys 58 ). The transmembrane domain presents a negatively charged residue (glutamic acid) in a central position and is followed by a very short cytoplasmic tail (7 residues) without any known signaling motif ( Fig 1A) . Through alignment of cDNA and genomic sequences we determined CD300d gene organization (Fig 1B) . The gene spans a 12.5-kb region of chromosome 17 (17q25.1) and is composed of four exons. The first exon encodes for the 5' untranslated region and the protein's signal peptide, whilst the Ig domain is encoded by exon 2, the membraneproximal region by exon3 and the transmembrane domain and cytoplasmic tail of CD300d by exon 4. We analyzed the degree of homology of the extracellular Ig domain of CD300d with sequences of CD300 family members and TREM-1, a closely related immunoreceptor. CD300f Ig domain showed the highest homology (71.4 % identity) with CD300d, while other members of the family such as CD300b (58.9%), CD300e (41.1%), CD300c (41.1%), and CD300a (39.2%), presented less but still significant homology (Fig 1C) . A lower degree of protein sequence homology was detected between the Ig domains of CD300d and other related proteins as CD300Lg and TREM-1 (31.2% and 17.8% respectively). The amino acid sequences of the Ig-like domain of all human CD300 molecules and TREM-1 were aligned and used to reconstruct a molecular phylogenetic tree using the Phylogeny.fr platform (16) . As expected from the identities mentioned above, CD300d is closely related to CD300f and CD300b. Interestingly, when we analyzed the homologies among the exons encoding for the transmembrane and intracellular domains of CD300 molecules, CD300c was the closest to CD300d. These data suggest that multiple gene duplications of CD300-related genes might have occurred along evolution, probably from a common ancestor with CD300Lg. CD300d expression is restricted to the myeloid lineage -To determine the distribution of CD300d transcript, we performed Real Time PCR on PBMC and purified blood populations as well as diverse hematopoietic cell lines. CD300d was found abundantly in PBMC but exclusively in the myeloid compartment, including monocytes and granulocytes populations (Fig 2A) . No cDNA amplification was observed in T, B and NK lymphocytes. Similarly to CD300e, CD300d transcript was absent in cell lines from myeloid origin (THP-1, U937, HL-60 and MonoMac6) in basal conditions (data not shown). Based on these data, CD300d expression seems to be restricted to cells of myeloid lineage, as we observed previously for CD300b, CD300e and CD300f (8, 9, 13) . To further analyze the pattern of expression of CD300d in monocyte-derived macrophages, we isolated monocytes from healthy donors and cultured them in the presence of GM-SCF to differentiate monocytes into naïve macrophages. Cells were further treated with cytokines to obtain activated macrophages from the different subtypes: IFN-γ (M1ca), IL-4 or IL-13 (M2a/IL-4 and M2a/IL-13) or IL-10 (M2c). We analyzed the expression of CD300d transcripts by real-time PCR. Amplification data showed a significant decrease of CD300d expression in all types of in vitro derived macrophages when compared with freshly isolated monocytes. In fact, CD300d transcript was undetectable in IL13-driven type II macrophages (Fig 2B) . Molecular/biochemical characterization of CD300d -The cDNA encoding for CD300d was cloned in the pDisplay vector in order to tag the protein with an N-terminus HA epitope and transiently transfect COS-7 cells. HA-CD300c was used as control, due to the high homology between both molecules in terms of predicted molecular weight and structure. Forty-eight hours post-transfection, cells were lysed and subjected to anti-HA immunoprecipitation and SDS-PAGE analysis. Despite CD300d had a predicted molecular weight of 21.5 kDa, the molecule appeared as discrete pattern of two bands around 30 and 34 kDa. CD300c showed a more complex pattern of bands with a retarded electrophoretic mobility (Fig 3A) . CD300d apparent molecular mass was reduced after in vitro N-deglycosylation with PNGase F indicating the presence of N-linked sugars in the protein backbone (Fig 3B) . Surprisingly, surface expression of HACD300d was almost undetectable on transfected COS-7 cells when assessed by flow cytometry, whereas around 25% of HACD300c transfected cells were positive for HA-staining (Fig 3C) . It is noteworthy that we could detect comparable amounts of both molecules when the expression was monitored by western blot (Fig 3A) . This data indicated that HA-CD300d was expressed efficiently but the molecule was retained intracellularly and its traffic towards the cell membrane was blocked. Considering that CD300d N-deglycosylation resulted in a molecular electrophoretic pattern close to the polypeptidic backbone, it was feasible that the receptor was blocked in the endoplasmic reticulum (ER). Accordingly O-glycans could not be transferred to the immature protein in the Golgi apparatus explaining the different mobility of CD300d in SDS-PAGE gels when compared with CD300c. To test the ERblockade, we fused CD300d receptor to GFP to allow protein visualization by means of fluorescence microscopy. CD300d-GFP was markedly concentrated in a perinuclear region upon transfection in COS-7 cells colocalizing with the ER marker BIP/GRP-78 (17) (Fig 3D) . Conversely, cells transfected with CD300c-EGFP showed a more disseminated pattern of expression compatible with a cell surface localization (Fig 3D) . The fact that CD300d was retained intracelullarly when the expression of all CD300 molecules was driven by the same promoter and an exogenous signal peptide, suggested the existence of a retention motif in the sequence of CD300d. We noted that 6 out of 7 aa present in CD300d cytoplasmic tail were identically represented in CD300c. Only position +6 showed a difference between both receptors being a serine in CD300c and an arginine in CD300d (Fig 4A) . In order to determine whether this residue constituted an ER retention motif, we carried out an HACD300d substitution mutant. CD300d R137S was unable to reach the cell surface upon transfection ( Figure 4B, left) , indicating that other domains in CD300d had to be involved in the intracellular retention of this molecule. Next, we evaluated the possibility that CD300c had an ER retrieval motif within its 12 aa-long cytoplasmic tail. With this purpose we used a CD300c deletion mutant lacking the cytoplasmic tail (CD300c ∆cyto) to evaluate its access to the cell surface compared to CD300c WT (12) . HA staining on COS-7 transfected cells showed no differences in the levels of expression of both constructs ( Figure 4B, middle) . Then, we made a chimerical protein containing the complete CD300d extracellular sequence and the transmembrane and cytoplasmic tail of CD300f receptor (CD300d/f). This construct was detected on the surface of COS-7 transfected cells similarly to CD300f WT, indicating that CD300d immunoglobulin domain and/or stem region were not responsible for CD300d intracellular entrapment (Fig 4B, right) . Next we generated a new chimerical protein harboring the extracellular and transmembrane region of CD300c and the cytoplasmic tail of CD300d (CD300c/d). As we show in figure 4B , this construct was detected on the surface of transfected cells equally well than CD300c. This data suggested that CD300d transmembrane region was involved in the intracellular retention. We noted the presence of two phenylalanine residues within CD300d transmembrane sequence that were not present in the same region of CD300c ( Fig  4A) . Thus, we substituted both residues in CD300d by a leucine and valine residues to generate a new CD300d construct, (F168L-F170V) with a transmembrane domain almost identically to CD300c. The substitution of both phenylalanine residues did not modify the intracellular expression of CD300d. Similarly, substitution of the CD300d transmembrane glutamic acid residue by an alanine (E173A) did not enhance the surface expression of the receptor (Fig 4B, left) . These data strongly suggest the existence of diverse retention-retrieval motifs present in more than one domain of CD300d that might be responsible for the intracellular retention observed for this protein.
CD300d recruits the ITAM-bearing adaptor
Fcε ε ε εRγ γ γ γ -We have shown recently that CD300c is able to deliver activating signals through the recruitment of the ITAM-bearing adaptor FcεRγ (12) . The binding between CD300c and FcεRγ was not based in the classical positive-negative charge complementation at the transmembrane region found in most of the activating immunoreceptors.
In fact, CD300c transmembrane glutamic acid, which was shown to be essential for the functionality of the receptor, was not required for FcεRγ recruitment (12) . CD300c is localized on the cell surface in the absence of FcεRγ, but cotransfection with the adaptor polypeptide enhances its surface expression (Fig 4C) . Due to the structural similarity between CD300c and CD300d, we decided to check whether cotransfection of CD300d with transmembrane adaptor proteins could impair its ER blockade. FcεRγ enabled the receptor's surface expression, whilst other myeloid transmembrane adaptor molecules such as DAP12 or DAP10 had slight or no effect on CD300d expression (Fig 4C) . It is worth mentioning that the cell surface expression of the transmembrane polypeptides remained constant (Supplemental Fig 1) . Next, we explored whether this effect occurred as consequence of a direct interaction between both molecules. FcεRγ immunoprecipitated together with CD300d receptor in COS-7 cells ( Figure 4D ). Indeed, CD300d recruited FcεRγ as efficiently as CD300c (Fig 4D) . In parallel, we demonstrated that CD300d was able to recruit the adaptor DAP12 as efficiently as CD300c. Finally, we analyzed the role of the negative residues within the transmembrane sequences of both CD300d and FcεRγ in the interaction between both proteins. Whereas the glutamic acid present in CD300d seemed not to be required for the interaction between the two proteins, substitution of the negative charge within the transmembrane domain of FcεRγ strongly decreased the interaction (Fig 4E) . CD300d interacts with all CD300 family members with the exception of CD300c -by guest on May 20, 2017 http://www.jbc.org/ Downloaded from CD300 receptors are able to interact with each other, even with themselves, forming both homo and heterodimers. These complexes are formed intracellularly, and the combination of CD300 receptors in a complex differentially modulates their signaling outcome (12) . The interactoma between CD300 receptors was determined for all members but CD300d which was not cloned at that moment. Surprisingly, CD300d formed complexes with all the members of CD300 family with the exception of CD300c in COS-7 overexpression system (Fig 5A) . In addition, CD300d was able to form homocomplexes (Fig 5B) . CD300d stably expressed in RBL-2H3 cells is not present on the cell surface -We have used extensively the RBL-2H3 cell line to analyze the function of CD300 receptors (8, 10, 12, 13) . We stably transfected this cell line with an HA-tagged form of CD300d receptor to be able to further analyze its function. Albeit RBL-2H3 cells express FcεRγ which was shown to be essential for CD300d surface export, the receptor could not be detected by flow cytometry. However, we could detect the presence of the protein by western blot (data not shown). Next, we reasoned that in RBL-2H3 cells CD300d export might rely on the presence of other CD300 molecules rather than on transmembrane adaptor proteins. In order to check this hypothesis, we transfected RBL-2H3 cells stably expressing Myc-CD300f or Myc-CD300c with HA-CD300d receptor. We expected that the formation of complexes between CD300f and CD300d would force CD300d expression on the cell membrane. By contrast, as CD300c and CD300d did not interact, our prediction was that no surface expression of CD300d will be detected. CD300d was not detected on the surface of RBL-2H3 independently of the CD300 receptor content. However, we noticed that CD300f expression was diminished when cells had been cotransfected with CD300d, whilst expression of CD300c was similar both in the presence and absence of CD300d ( Fig  6A) . It is of mention that both cell lines were successfully transfected with CD300d as determined by western blot techniques ( Fig  6B) . CD300d downregulates CD300f surface expression in transiently transfected COS-7 cells -The reduced levels of CD300f in the cell surface in the presence of CD300d pointed out the possibility that CD300d function would be to negatively regulate the expression of CD300 molecules on the cell surface. To this aim, we measured the cell surface levels of CD300f and CD300c both in the presence and absence of CD300d. Cotransfection of CD300d significantly decreased the presence of CD300f on the cell surface ( Fig 7A) . As expected, CD300d had no effect on CD300c cell surface expression. Again, equivalent amounts of CD300d were detected in transfected cells when assessed by western-blotting (Fig 7B) .
DISCUSSION
With the cloning and characterization of CD300d we have completed the description of the human CD300 locus. As shown in figure 1B , six members (from CD300a to CD300f) are clustered in a 450 kb region of human chromosome 17. Some kb upstream, there is a seventh gene encoding for a receptor named nepmucin/CD300Lg (18, 19) . Despite the homology of CD300Lg Ig domain with the rest of CD300 members, there are multiple reasons that convert this receptor in a distant member of the family. CD300Lg is the only member containing an extracellular mucin-like domain. The cellular and tissue distribution of CD300Lg is restricted to endothelial cells and its role in L-selectin dependent lymphocyte rolling and adhesion is totally unrelated with the activating/inhibitory capabilities of CD300 immunoreceptors. The most interesting finding concerning CD300d receptor is its inability to reach the cell membrane when transfected in multiple cell types. CD300d was retained intracellularly and more specifically within the ER. Retention within this organelle is partly aided by the linear signals -KDEL and -K(x)Kxx, which represent well-characterized ER-localization signals for lumenal and membrane proteins, respectively. However, other motifs less well-characterized have been implicated in this process. Type I transmembrane proteins display KKxx or dileucin (LL) motifs within their cytoplasmic tails, while type II molecules bear argininebased motifs at the N-terminus of the transmembrane domain. Interestingly, at least two type I proteins, VIP36-like and TMX4, have been shown to present arginine-based ER-localization motifs within their cytoplasmic tails (20, 21) . CD300d sequence analysis revealed the presence of a di-arginine motif within its cytoplasmic tail differentially to CD300c. However, disruption of this motif by mutagenesis did not conduce to CD300d surface expression. Protein export from ER is a selective process driven by COPII-coated transport vesicles and dictated by short, linear sequences called ER export motifs (22) . These motifs interact with components of the transport vesicles, leading to increased concentration of cargoes in ER exit sites and the subsequent recruitment onto the COPII vesicles. Of various ER export motifs identified, the di-acidic motifs have been found in the cytoplasmic and membranedistal C termini of several membrane proteins (23) . CD300d cytoplasmic tail was ruled out to regulate the trafficking of the receptor due to the fact that the remaining residues within this unit were coincident with CD300c. Additionaly, CD300 receptors do not seem to bear ER-release motifs within intracellular domains as CD300c and CD300f cytoplasmic deletion mutants maintained a cell surface phenotype (10, 12) . Of special interest is the case of the high affinity receptor for IgE (FcεRI). In humans this receptor is found in two alternative forms. The trimeric form is composed by the IgE-binding α subunit (FcεRα) and a disulfide-linked homodimer of γ chains, whilst the tetrameric form contains an additional tetraspanning β chain (FcεRβ) (24) . FcεRα contains an acidic residue in its transmembrane domain and a short cytoplasmic tail, similarly to CD300c and CD300d. FcεRα displays two di-leucine ER retention motifs in its cytoplasmic tail but they are masked by the association with FcεRγ, allowing its targeting to the cell membrane (25) . Nevertheless, this regulation does not occur constitutively as in eosinophils and megakaryocytes FcεRα is accumulated in intracellular compartments despite the presence of FcεRγ in those cells (26, 27) . It is of note that additional mechanisms controlling the surface expression of FcεRα related with its signal peptide (28) and with the N-glycosylation of asparagine residues within its immunoglobulin domain have been described (29) . Signal peptide is not responsible for CD300d retention.
Entrapment occurred equivalently using three different constructs in which the receptor was driven by different signal peptides: Igκ-chain leader sequence in pDisplay, CD8α leader sequence in pCDNA3-FLAG and its own signal peptide in pEGFP-N3. Extracellular domain might also be ruled out as substitution of Ig domain and stem regions of CD300f by CD300d resulted in a chimerical protein able to reach the cell membrane. Our experiments with chimerical proteins point out to the transmembrane domain of CD300d as the ER-retention unit, but the substitution of the two phenylalanine residues and the glutamic acid present in this region were not able to induce the trafficking towards the cell surface. Taken together, our data suggest a complex scenario were the combination of different retention-retrieval motifs in different domains of CD300d might be responsible for the intracellular location of this protein.
The presence of FcεRγ was able to overcome CD300d ER retention in COS-7 cells, while no receptor was detected in the surface of RBL-2H3, where FcεRγ is endogenously expressed (12) . FcεRγ could mask CD300d putative retention motifs in a similar way to what has been described for FcεRα. In addition, it has been suggested that transmembrane adaptor proteins might act not only as signaling modules but also as chaperones for certain immunoreceptors. Early events in the folding of the receptor are probably rate-limiting and that receptor folding intermediates are retained in the ER until they can adopt the correct conformation and the fully glycosylated pattern. Formation of stable receptor-adaptor modules is thought to assist this process and prevent intracellular degradation. This is the case for NKG2C and Ly-49 whose expression in the membrane is dependent on DAP12 (30, 31) . However, it is of note that all CD300 activating members (CD300b, CD300c and CD300e) could be expressed on the surface of transfected COS-7 cells independently of the presence of the transmembrane adaptor polypeptides to which they associate, although presence of those ITAM-bearing adaptors could enhance the levels of expression on the cell surface. Curiously, whereas co-transfection of CD300d and CD300c with FcεRγ enhanced the surface expression of both receptors, cotransfection with DAP12 did not produce the same effect (Fig 4C) . By contrast, we have shown previously that the presence of DAP12 augmented the presence of CD300b on the surface of co-transfected COS-7 cells (9) . This data strongly suggests that the interaction between ITAM-bearing adaptors and receptors is more complex than expected. In fact, immunoreceptors recruiting ITAMbearing adaptors could be classified according to the structural elements involved in the establishment of the interaction (1). First, the classical immunoreceptors, that binds to these adaptors through a mechanism of positive-negative charge complementation at the transmembrane level. This is the case for the receptors belonging to the KIR, ILT and TREM families. And second, the non-classical immunoreceptors, that would bind to the signaling adaptors independently of the presence of charged residues within the transmembrane domain of the receptors, although the presence of a negative charge in the adaptors seems to be important for the interaction. This last group includes integrins, growth factor receptors and MHC proteins (1) . We can include in this group those receptors bearing a negative charge within its transmembrane domain such us CD300c (12), CD300d (Fig 4E) and the IgE-binding α subunit (FcεRα) (24) . Interestingly, within the CD300 family, we find members binding the adaptor polypeptides both in a charge-dependent (CD300b and CD300e) and independent (CD300c and CD300d) manner.
The lack of specific antibodies against CD300d makes difficult to define the location of this receptor in monocytes and granulocytes, which are positive for the receptor at the mRNA level. It is evident that the cellular compartmentalization would determine CD300d function. Our experiments show that CD300d is able to recruit the ITAM bearing adaptor FcεRγ, suggesting that if this receptor is able to reach the cell surface could deliver activating signals after engagement with a specific ligand similarly to CD300c (12) . We have shown recently that CD300 molecules have the capability to interact each other trough their Ig domain. The combination of CD300 receptors in the cells surface complexes modulate differentially the signaling outcome in transfected cells (12) , suggesting a new mechanism by which CD300 complexes could finely regulate the activation of myeloid cells upon interaction with their natural ligands. In this context, the CD300d ER-confinement could serve to modify the extracellular expression of some CD300 receptors and as consequence controlling the composition of CD300 surface complexes. Indeed, ER export has been shown to be a rate-limiting step for the cell surface transport of the receptors (32) . This hypothesis has been validated both in COS-7 and RBL-2H3 cells where CD300d reduced CD300f cell surface levels. Accordingly, CD300c membrane content was not modified by CD300d as consequence of the lack of interaction between these two receptors. In addition, despite our co-transfection experiments have not induced the surface expression of CD300d in the presence of CD300f, we can not discard that in real cells CD300d surface expression require the formation of intracellular complexes with other CD300 molecules as CD300a, CD300b or CD300e. Taken together, we have cloned and molecularly characterized CD300d, the sixth member of the human CD300 family of immunoreceptors. Our data suggest that CD300d, expressed exclusively in monocytes and granulocytes, could play a role in the regulation and/or formation of CD300 complexes on the cell surface and consequently modulate the state of activation of myeloid cells. . (B, C) COS-7 cells were transiently transfected with HA-tagged CD300c, CD300d and CD300f WT or mutants constructs and/or FLAG-tagged transmembrane adaptor molecules. Forty-eight hours post-transfection cells were subjected to flow cytometry to asses the cell surface expression of the desired molecules. CD300 receptors were stained using anti-HA (12CA5) (white histograms). An isotypic mAb was used as negative control (grey histograms). (D, E) Transfected COS-7 cells lysates were immunoprecipitated with anti-HA (11) mAb. Proteins were analyzed in 15% SDS-PAGE under reducing conditions, transferred to PVDF and probed with the indicated antibodies. Whole cell lysates (2%) were included as controls. 
